Method for screening anti-tumor agents of the reticulo-endothelial stimulant class
OwnerJulian W. Proctorinventor
Life of this patent
Estimating the term…
Abstract
A procedure is disclosed for determining optimal doses, scheduling, routes of administration, the time for initiation, the magnitude and the duration of the anti-tumor effects, at various times following the administration to laboratory test animals such as rodents of doses of reticulo-endothelial stimulants by convenient anatomical routes. Following administration of the reticuloendothelial stimulant material the animals are challenged intravenously with radiolabelled tumor cells, and after 1 to 24 hours they are sacrificed, the lungs harvested and counted for radioactivity. The method allows for comparative studies on a number of agents and can be used as a screening assay as well as for the quality control of existing products.
Claims4
A method for determining the anti-tumor activity of an agent of the reticulo-endothelial stimulant class comprising the sequential steps of:
- (1) administering predetermined doses of an anti-tumor agent of the reticulo-endothelial stimulant class to a rodent, by a suitable route of administration;
- (2) at between 2 and 60 days, thereafter, administering a predetermined quantity of radiolabelled tumor cells, radiolabelled with a DNA label, to said rodent;
- (3) allowing the administered radiolabelled tumor cells to build up in the lung and subsequently allowing at least about 50% of said cells to be lost from the lung of said rodent;
- (4) isolating the lung tissue from said rodent and measuring the radioactivity emanating from the remaining radiolabelled tumor cells in said isolated piece of tissue;
- and thereafter
- (5) calculating the increase in loss of said radioactivity from said isolated piece of lung tissue of a predetermined size from animals treated with said anti-tumor agent of the reticulo-endothelial stimulant class, compared with the loss of radioactivity from a piece of lung tissue of substantially the same predetermined size isolated from rodents receiving no or a placebo treatment, the increase representing an index of the magnitude of the anti-tumor effect observed.
A method for determining the anti-tumor activity of an agent of the reticulo-endothelial stimulant class comprising the sequential steps of:
- (1) administering predetermined doses of an anti-tumor agent of the reticulo-endothelial stimulant class to a rodent by a suitable route of administration, said agent selected from the group consisting of C. parvum, glucan compounds, BCG compounds, Lipopolysaccharide, muramyl dipeptides, and NVE's;
- (2) at between 2 and 60 days, thereafter, administering a predetermined quantity of radiolabelled tumor cells, radiolabelled with a DNA label, to said rodent;
- (3) allowing the administered radiolabelled tumor cells to build up in the lung and subsequently allowing at least about 50% of said cells to be lost from the lung of said rodent;
- (4) isolating the lung tissue from said rodent and measuring the radioactivity emanating from the remaining radiolabelled tumor cells in said isolated piece of tissue;
- and thereafter
- (5) calculating the increase in loss of said radioactivity from said isolated piece of lung tissue of a predetermined size from animals treated with said anti-tumor agent of the reticulo-endothelial stimulant class, compared with the loss of radioactivity from a piece of lung tissue of substantially the same predetermined size isolated from rodents receiving no or a placebo treatment, the increase representing an index of the magnitude of the anti-tumor effect observed.
Dependencies are inferred from the claim text.